Effectiveness of Proprioceptive Neuromuscular Facilitation Technique on Paclitaxel Chemotherapy Induced Motor Dysfunction and Activities of Daily Living in Breast Cancer Survivors. - A Randomized Controlled Trial

Abstract

Background: Breast cancer remains one of the most common cancers affecting women worldwide, with chemotherapy being a prevalent treatment modality. Among the various chemotherapeutic agents, Paclitaxel is widely used due to its efficacy in targeting cancer cells. However, despite its therapeutic benefits, Paclitaxel is associated with several adverse effects, including peripheral neuropathy, which can lead to significant motor dysfunction. his neuropathy manifests as muscle weakness, impaired coordination, and reduced fine motor skills. Motor dysfunction in breast cancer survivors undergoing Paclitaxel chemotherapy often translates to substantial difficulties in performing activities of daily living (ADLs). ADLs encompass essential self-care tasks such as bathing, dressing, eating, and mobility. Impairments in these areas can lead to increased dependence, decreased independence, and overall diminished quality of life. Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic approach that has shown promise in improving neuromuscular control and functional abilities. The methodology focuses on stimulating proprioceptors, which are sensory receptors that provide information about body position and movement. By engaging these receptors, PNF aims to improve the communication between the nervous system and muscles, thereby enhancing motor function and control. Despite the theoretical benefits, there is limited empirical evidence supporting the use of PNF specifically for Paclitaxel-induced motor dysfunction. This randomized controlled trial aims to fill this gap by rigorously evaluating the effectiveness of PNF in improving motor function and ADLs in breast cancer survivors. By providing robust data, this study seeks to establish PNF as a viable and effective rehabilitation option for this population, ultimately contributing to improved long-term outcomes and quality of life for breast cancer survivors.

Objective: To evaluate the effectiveness of Proprioceptive Neuromuscular Facilitation (PNF) in mitigating motor dysfunction and enhancing ADLs in breast cancer survivors treated with Paclitaxel.

Methods: This randomized controlled trial included 60 breast cancer survivors experiencing Paclitaxel-induced motor dysfunction. Participants were randomly assigned to either the intervention group, receiving PNF therapy, or the control group, receiving standard care. The intervention group underwent PNF sessions three times a week for 4 weeks. Outcomes were assessed using the and the Activities of muscle strength by 1 RM and ADLs by using L-IADLs before and after the intervention.

Results: The intervention group demonstrated significant improvements in 1RM compared to the control group (p < 0.05). Additionally, L-IADLs scores indicated a notable enhancement in the ability to perform daily activities for participants receiving PNF (p < 0.05). These improvements were observed as early as 4 weeks

Conclusion: PNF therapy is effective in reducing Paclitaxel-induced motor dysfunction and improving the quality of life by enhancing ADLs in breast cancer survivors. This therapeutic approach offers a viable rehabilitation option, potentially leading to better long-term functional outcomes for this population